Juliette White, VP of Sustainability at AstraZeneca, outlines the company's sustainability strategy and progress towards its climate goals. The strategy focuses on three priorities - access to healthcare, environmental protection, and ethics - through nine focus areas. A key priority is Ambition Zero Carbon, with goals to reduce greenhouse gas emissions 98% by 2026 and become carbon negative by 2030. Over 96% of AstraZeneca's carbon footprint comes from its supply chain. The company is engaging suppliers and partners to accelerate decarbonization through initiatives like Energize for renewable energy procurement and responsible sourcing standards.

1. Juliette White,
VP Sustainability and
Global SHE, AstraZeneca
Building Sustainable Supply Chains

2. Taking action to
drive
sustainability is
fundamental
– for the health of
people, society,
and the planet
April 2022
2
Taking action to
drive
sustainability is
fundamental
– for the health
of people,
society, and the
planet

3. November 2022
3
How we are delivering our Sustainability strategy
Our three interconnected sustainability priorities Access to healthcare, Environmental protection, and
Ethics and transparency are underpinned by nine focus areas where we believe we can make the most impact.
Equitable
access
Affordability
and pricing
Health system
resilience
Ethical business
culture
Inclusion and
diversity
Workforce safety
and health
Ambition Zero
Carbon
Product
sustainability
Natural
resources
Sustainability
at AstraZeneca

4. November 2022
4
Ambition Zero Carbon
Approach
Ambitious science-based decarbonisation strategy,
accelerating our progress towards net zero.
From 2026, we will have
reduced our Scope 1
and 2 GHG emissions by
98%, by:
• Switching to a fully
electric vehicle fleet
• Using 100% renewable
energy for heat and
power
• Doubling energy
productivity
• Eliminating F-Gas
emissions at our sites
We will become carbon
negative across our value
chain by 2030, our Scope 3,
and have committed to:
• 95% of key suppliers and
partners having science-based
targets by the end of 2025
• Transitioning to next-generation
respiratory products with near-
zero climate impact propellants
• ‘Designing in’ sustainability across
product lifecycles and embedding
net zero into cost of goods
We were one of the first
seven companies
worldwide to have our
net zero, science-based
Scope 1-3 GHG emissions
reduction targets verified
under the new Science
Based Targets initiative
Net-Zero Corporate
Standard. We aim to be
net zero by 2045.

5. 5
What makes up our carbon footprint?
AstraZeneca
2021
corporate
footprint1
4% 96%
Scope 3
Our indirect footprint —
our value chain
Scopes 1 and 2
Our direct and indirect
footprint — emissions
from the combustion of
fuels
F

6. Achievements
$130M invested in natural
resource efficiency projects
since 2015
59% reduction in GHG since
2015
100% imported renewable
electricity globally
% 64 green fleet
(EV, hybrid or plug-in hybrid)
Agreement signed with Future
Biogas for renewable heat in UK
Ambition Zero Carbon achievements
November 2022
6
2020 2021
Achievements
Launched Ambition
Zero Carbon
First climate impact
disclosure to TCFD
Achievements
Launched the
Energize programme
Launched the
Product Sustainability
Index
Achievements
First pharma to join all 3
of Climate Group’s
Signed up to UN Race to
Net Zero
2022
Achievements
Honeywell Partnership
announced
for low GWP
propellants
40% of suppliers spend
with suppliers who
have SBTs

7. Engaging our
supply chain
November 2022
7
• Collective action is critical to
transforming global supply chains.
• To achieve our net zero by 2045 goal
we are engaging across our entire
value chain.
• And working with partners across
private and public sectors to
accelerate the delivery of net zero,
patient-centric, healthcare.

8. Sustainable Markets Initiative (SMI)
Health Systems Task Force
• Championed by our Chief Executive Officer, Pascal Soriot.
• Brings together leaders from public and private sectors to accelerate net
zero healthcare.
• COP27: 7 Task Force CEOs from AstraZeneca, GSK, Merck KGaA, Novo
Nordisk, Roche, Samsung Biologics and Sanofi aligned on targets in line
with 1.5C, including commitment to:
• Aligning on a common supplier standards to incentivise
decarbonisation efforts across the supply chain.
• Jointly pursuing renewable power purchase agreements.
November 2022
8
Dr. Tedros, DG, WHO
Pascal Soriot at COP27

9. • First-of-its-kind initiative to support suppliers in accessing renewable energy.
• Renewable energy procurement can be challenging for companies of all sizes.
• Energize designed to overcome typical market barriers: inadequate knowledge about
renewable energy transactions, load size, lack of credit, and need for guidance.
• By switching to renewables, suppliers will reduce their Scope 2 emissions, enabling us to
in-turn reduce our Scope 3 emissions.
• Represents a powerful step towards our 2030 goal.
November 2022
9
Energize – cross-pharma renewable energy
project

10. Responsible supply chain
November 2022
10
Ecovadis
• Scorecard allows AstraZeneca to understand:
• Environmental, ethical and social performance
of our suppliers
• Supplier sustainability maturity, and the risks
and opportunities across our supplier base
• In 2021, we requested that 36% of our suppliers
by spend took the assessment.
• Enables industry collaboration across our supply
chain through collective monitoring of
performance.
Pharmaceutical Supply Chain Initiative (PSCI)
• We are active members of PSCI. Partners are
expected to follow the PSCI Principles:
• Operate in full compliance with their local
legal requirements as well as national and
international regulations
• Continuously improve their performance in
the areas of labour, health, and safety

11. Circular
economy
Design out waste
Use renewable resources
and regenerate nature
Minimise material
use and waste
Increase reused or
recycled content
Maximise recycling
and eliminate
waste to landfill
Apply metrics to
measure progress
Embracing a circular economy

12. THANK YOU